The Basics
What is Tagraxofusp?
For the treatment of blastic plasmacytoid dendritic cell neoplasm.
Brand names for Tagraxofusp
Elzonris
How Tagraxofusp is classified
Antineoplastic Agents, Recombinant Fusion Proteins
Tagraxofusp During Pregnancy
Tagraxofusp pregnancy category
Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Tagraxofusp while pregnant
N/A
Taking Tagraxofusp While Breastfeeding
What are recommendations for lactation if you're taking Tagraxofusp?
No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose.
Maternal / infant drug levels
No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose.
Possible effects of Tagraxofusp on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Tagraxofusp
None listed
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/None listed
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
